Voya Investment Management LLC boosted its stake in Intersect ENT, Inc. (NASDAQ:XENT) by 9.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,724 shares of the medical equipment provider’s stock after acquiring an additional 1,128 shares during the period. Voya Investment Management LLC’s holdings in Intersect ENT were worth $356,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in Intersect ENT by 3.8% in the 2nd quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares in the last quarter. Prudential Financial Inc. purchased a new stake in Intersect ENT in the 2nd quarter valued at approximately $229,000. California Public Employees Retirement System purchased a new stake in Intersect ENT in the 2nd quarter valued at approximately $260,000. Personal Capital Advisors Corp purchased a new stake in Intersect ENT in the 2nd quarter valued at approximately $273,000. Finally, American International Group Inc. boosted its holdings in Intersect ENT by 7.1% in the 1st quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after purchasing an additional 1,037 shares in the last quarter. Hedge funds and other institutional investors own 83.08% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Voya Investment Management LLC Buys 1,128 Shares of Intersect ENT, Inc. (XENT)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/12/voya-investment-management-llc-buys-1128-shares-of-intersect-ent-inc-xent.html.

In other news, CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total transaction of $398,464.65. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares in the company, valued at approximately $864,214.65. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $30.79, for a total value of $615,800.00. Following the sale, the insider now owns 525,868 shares of the company’s stock, valued at $16,191,475.72. The disclosure for this sale can be found here. Insiders sold a total of 134,563 shares of company stock valued at $3,999,247 over the last quarter. 13.70% of the stock is currently owned by insiders.

Intersect ENT, Inc. (NASDAQ:XENT) opened at $28.15 on Friday. Intersect ENT, Inc. has a 12-month low of $9.20 and a 12-month high of $33.25.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. The company had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. Intersect ENT’s revenue was up 20.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) EPS. equities analysts predict that Intersect ENT, Inc. will post -0.63 EPS for the current year.

A number of brokerages have weighed in on XENT. BTIG Research reaffirmed a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Intersect ENT in a report on Friday, November 3rd. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Canaccord Genuity boosted their price target on Intersect ENT from $32.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. Finally, Bank of America Corporation boosted their price target on Intersect ENT from $33.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $30.88.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.